CCL5 and fatty liver disease: Of note, apart from binding to ISRE promoter elements [78], IRF3 has been reported to bind ISRE-like elements and activate the RANTES promoter [79], or bind to IRF3-binding sites within the SCD1 promoter to repress Scd1 transcription and prevent hepatic steatosis [80].